Plandai Biotechnology Issues Business Targets and Milestones for Remainder of 2018

Looking to Ramp Commercialization and Accelerate Revenue Growth

LONDON, UNITED KINGDOM, March 20, 2018 (GLOBE NEWSWIRE) -- Plandaí Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandaí”), a producer of nutraceutical and highly phyto-available extracts, today announced business objectives, targets and milestones for the remainder of 2018.

Plandaí is excited with the development and progress of its Phytofare® extracts as it delivers a more meaningful and beneficial dose at highly competitive prices to the consumer. The Company has identified and is targeting three industries to accelerate its revenue growth.

 First, in 2017, Plandai conducted preliminary investigations and research into developing a Phytogenic feed supplement for use in animal husbandry. This included doing multiple preliminary clinical studies with the aim of improving animal wellness across the broad animal husbandry sector. The results thus far have been outstanding, and the Company is currently working to complete its trials.  When the latest trials are completed and the results made available for release, the company will issue a further press release discussing the findings and the Company’s future plans. Roger Duffield, the Company’s director and Chief Science Officer assigned to the tests, commented: “We are encouraged and excited about the significant potential impact that these results may have across multiple animal related industries.”

 Second, the Company has developed targeted nutraceutical supplements to enhance health and wellness for consumers which were launched last year.  After struggling a bit to find its niche, Phytofare® is now finally building in sales momentum.  We have contracts with several large, international nutraceutical customers and developed a private label product with Coyne Healthcare that has been selling well.  Coyne is targeting a major product launch in the United States this year and we are excited to see our shareholders finally have the opportunity to see Phytofare® on the shelves at their local stores.

 Finally, last year Plandaí conducted a primate bioavailability study in Mauritius designed to help set target dosage for an upcoming diabetes human clinical trial.  The diabetes products will incorporate Phytofare® entrapped in a unique liposome delivery system designed to further heighten our already industry-leading level of bioavailability.  Before starting a human clinical trial, it was necessary to first determine dosage points and wash out periods.  The results from the new bioavailability study are expected to be released by the end of June, and management can then set the clinical trial protocols for our human diabetes study.  That study will assess the ability of Phytofare® to help regulated blood sugar and insulin levels in Type II diabetics.

 About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. (OTC Markets: PLPL) develops highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company's products include animal husbandry, dietary supplements and diabetes. Plandai Biotechnology is headquartered in London, United Kingdom. For more information, please visit:  

 Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company's filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.


Contact Data